Loading cancer entity…
Loading cancer entity…
Clinical trials
673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02924324 | Local Injection of Pain Medication to Reduce Pain After Bone Marrow Procedures in Pediatric Neuroblastoma Patients | completed | N/A | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT01767194 | Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma | completed | Phase 2 | 73 | National Cancer Institute (NCI)NIH | 5 | Oct 24, 2022 |
| clinicaltrials |
| NCT02035137 | 131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat(N2011-01) | completed | Phase 2 | 114 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jun 8, 2022 | clinicaltrials |
| NCT00072358 | Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma | completed | Phase 2 | 291 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 16, 2022 | clinicaltrials |
| NCT00567567 | Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma | completed | Phase 3 | 665 | Children's Oncology GroupNETWORK | 6 | Apr 28, 2022 | clinicaltrials |
| NCT00492167 | Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma | completed | Phase 1 | 45 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2022 | clinicaltrials |
| NCT02982941 | Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors | completed | Phase 1 | 25 | MacroGenicsINDUSTRY | 1 | Feb 8, 2022 | clinicaltrials |
| NCT02452554 | Lorvotuzumab Mertansine in Treating Younger Patients With Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma | completed | Phase 2 | 62 | Children's Oncology GroupNETWORK | 1 | Jan 13, 2022 | clinicaltrials |
| NCT01542736 | Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET) | completed | Phase 2 | 8 | University of Colorado, DenverOTHER | 1 | Jan 11, 2022 | clinicaltrials |
| NCT03042416 | 18F-DOPA PET Imaging: an Evaluation of Biodistribution and Safety | completed | Phase 3 | 400 | University of AlbertaOTHER | 1 | Jan 10, 2022 | clinicaltrials |
| NCT03291080 | Oral Liquid 13-cis-retinoic Acid (13-CRA)(My-CRA) | completed | Phase 1 / Phase 2 | 20 | Nova Laboratories LimitedINDUSTRY | 1 | Oct 19, 2021 | clinicaltrials |
| NCT01869725 | Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT | completed | Phase 2 | 68 | Sue O'DorisioOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT01619865 | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors(GA-68) | completed | Phase 1 / Phase 2 | 223 | Sue O'DorisioOTHER | 1 | Jul 27, 2021 | clinicaltrials |
| NCT01217437 | Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors | completed | Phase 2 | 108 | National Cancer Institute (NCI)NIH | 5 | Jul 23, 2021 | clinicaltrials |
| NCT02798406 | Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects(CAPTIVE) | completed | Phase 2 | 49 | DNAtrix, Inc.INDUSTRY | 2 | Jul 15, 2021 | clinicaltrials |
| NCT00499616 | Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma | completed | Phase 3 | 464 | Children's Oncology GroupNETWORK | 6 | Jul 6, 2021 | clinicaltrials |
| NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | completed | Phase 1 / Phase 2 | 36 | Cancer Research UKOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01662804 | Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors | completed | Phase 1 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT00536601 | High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors | completed | N/A | 174 | Roswell Park Cancer InstituteOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT02441062 | Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors | completed | Phase 2 | 122 | Sue O'DorisioOTHER | 1 | Dec 21, 2020 | clinicaltrials |
| NCT02159443 | Pretreatment Anti-Therapeutic Antibodies (PATA) in Patients Treated With hu14.18K322A Antibody | completed | — | 76 | St. Jude Children's Research HospitalOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT01704872 | ch14.18/CHO Bridging Study | completed | Phase 1 | 16 | St. Anna KinderkrebsforschungOTHER | 3 | Oct 22, 2020 | clinicaltrials |
| NCT00026780 | Eligibility Screening for a NCI Pediatric Oncology Branch Research Study | completed | — | 1,720 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2020 | clinicaltrials |
| NCT01467986 | Multimodal Molecular Targeted Therapy to Treat Relapsed or Refractory High-risk Neuroblastoma(RIST-rNB-2011) | completed | Phase 2 | 130 | University of RegensburgOTHER | 1 | Oct 6, 2020 | clinicaltrials |
| NCT00939770 | Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma | completed | Phase 1 / Phase 2 | 122 | Children's Oncology GroupNETWORK | 2 | Jun 9, 2020 | clinicaltrials |
| NCT01331135 | Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors(Aflac ST0901) | completed | Phase 1 | 18 | Emory UniversityOTHER | 1 | May 29, 2020 | clinicaltrials |
| NCT01154816 | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia | completed | Phase 2 | 118 | Children's Oncology GroupNETWORK | 2 | May 13, 2020 | clinicaltrials |
| NCT02390843 | Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors(AflacST1402) | completed | Phase 1 | 13 | Emory UniversityOTHER | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00578864 | Protracted Etoposide During Induction Therapy for High Risk Neuroblastoma(PEPI) | completed | Phase 2 | 13 | Baylor College of MedicineOTHER | 1 | Mar 27, 2020 | clinicaltrials |
| NCT02786719 | High-Risk Neuroblastoma Chemotherapy Without G-CSF(SPRING) | completed | N/A | 13 | Baylor College of MedicineOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT02100930 | Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma | completed | N/A | 69 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 28, 2020 | clinicaltrials |
| NCT00007813 | Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors | completed | Phase 1 | 21 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01222780 | To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer | completed | Phase 1 | 22 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 18, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT01445379 | Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer | completed | Phase 1 | 33 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00994071 | A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors | completed | Phase 1 | 9 | National Cancer Institute (NCI)NIH | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01114555 | Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory Neuroblastoma | completed | Phase 2 | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01492673 | Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma | completed | Phase 2 | 9 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 29, 2019 | clinicaltrials |
| NCT01334515 | Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma | completed | Phase 2 | 52 | Children's Oncology GroupNETWORK | 2 | Oct 21, 2019 | clinicaltrials |
| NCT01183416 | High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation | completed | Phase 2 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 9, 2019 | clinicaltrials |
| NCT01418495 | Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma | completed | — | 12 | National Cancer Institute (NCI)NIH | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01183429 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01183897 | 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow | completed | Phase 2 | 31 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01601535 | Study of MLN8237 in Combination With Irinotecan and Temozolomide | completed | Phase 1 / Phase 2 | 54 | New Approaches to Neuroblastoma Therapy ConsortiumOTHER | 2 | Jul 31, 2019 | clinicaltrials |
| NCT01460901 | Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma(STALLONe) | completed | Phase 1 | 5 | Children's Mercy Hospital Kansas CityOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT00436852 | ABT-751 in Treating Children With Neuroblastoma That Has Relapsed or Not Responded to Previous Treatment | completed | Phase 2 | 92 | Children's Oncology GroupNETWORK | 2 | Jul 17, 2019 | clinicaltrials |
| NCT00126412 | Meta-Iodobenzylguanidine (123I mIBG) Scintigraphy in Patients Being Evaluated for Phaeochromocytoma or Neuroblastoma | completed | Phase 3 | 251 | GE HealthcareINDUSTRY | 1 | May 31, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Nov 8, 2022source: clinicaltrials